Skip to main content

Table 1 Demographic and clinical characteristics

From: Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment

  Training cohort Test cohort  
Characteristics Number (%) Number (%) P value
Case 139 (100.0%) 139 (100.0%)  
Age (y)    0.628
 ≤ 45 58 (41.7%) 62 (44.6%)  
 ≥ 46 81 (58.3%) 77 (55.4%)  
cT stage    0.521
T1 15 (10.8%) 11 (7.9%)  
T2 83 (59.7%) 92 (66.2%)  
T3 27 (19.4%) 20 (14.4%)  
T4 14 (10.1%) 16 (11.5%)  
cN stage    0.200
N0 19 (13.7%) 9 (6.5%)  
N1 75 (54.0%) 76 (54.7%)  
N2 27 (19.4%) 35 (25.2%)  
N3 18 (12.9%) 19 (13.7%)  
ypT stage    0.360
T0 52 (37.4%) 49 (35.0%)  
T1 63 (45.3%) 75 (53.6%)  
T2 20 (14.4%) 12 (8.6%)  
T3 4 (1.4%) 4 (1.4%)  
ypT stage    0.332
T0 64 (46.0%) 53 (38.1%)  
T1 36 (25.9%) 43 (30.9%)  
T2 24 (17.3%) 32 (23.0%)  
T3 15 (10.8%) 11 (7.9%)  
pCR    0.887
pCR 33 (23.7%) 32 (23.0%)  
Non-pCR 106 (76.3%) 107 (77.0%)  
ER status    0.708
Positive 90 (64.7%) 87 (62.6%)  
Negative 49 (35.3%) 52 (37.4%)  
PR status    0.400
Positive 77 (55.4%) 70 (50.4%)  
Negative 62 (44.6%) 69 (49.6%)  
HER-2 status    0.694
Positive 96 (69.1%) 99 (71.2%)  
Negative 43 (30.1%) 40 (28.8%)  
Adjuvant chemotherapy    0.462
Yes 81 (58.3%) 87 (62.6%)  
No 58 (41.7%) 52 (37.4%)  
IMNI    0.407
Yes 32 (23.0%) 38 (27.3%)  
No 107 (77.0%) 101 (72.7%)  
Anti-HER2 therapy    0.971
Yes 11 (15.7%) 11 (15.9%)  
No 59 (84.3%) 58 (84.1%)  
Hormonal therapy    0.622
Yes 32 (23.0%) 32 (23.0%)  
No 102 (73.4%) 105 (75.5%)  
Unknown 5 (3.6%) 2 (1.4%)  
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, pCR pathologic complete response, NAC neoadjuvant chemotherapy, IMNI internal mammary node irradiation